Howard J. Leonhardt
Founder, Chairman & CEO Bioheart Inc.
BIOHEARTINC.COM | * View Resume *

Howard J. Leonhardt is the founder of the Bioheart Companies and has served as Chairman and Chief Executive Officer of the Company and each of the Affiliates since they were incorporated in August and September 1999. In 1986 Mr. Leonhardt founded World Medical Corporation and World Medical Manufacturing Corporation and served as CEO of both companies. World Medical Corporation was an export trading company specializing in cardiovascular devices and drugs. World Medical Manufacturing Corporation initially produced cardiovascular balloon catheters and later progressed into development of various other products including stent grafts for aortic aneurysm repair. In December 1998 World Medical Manufacturing Corporation was acquired by merger with Arterial Vascular Engineering, Inc. ("AVE") for $62 million market value of AVE's shares. Mr. Leonhardt is an inventor with patents and patents pending on nearly a dozen cardiovascular related devices. Mr. Leonhardt was the inventor of World Medical's primary product, the TALENT (Taheri-Leonhardt) stent graft system working in cooperation with Dr. Syde Taheri. From December 1998 through June 1999 Mr. Leonhardt held the position of President of World Medical as a subsidiary of Medtronic, Inc. (a medical technology company that purchased AVE after the merger), and has been a consultant to Medtronic since December 1999. Since June 1999, Mr. Leonhardt has been engaged primarily in efforts to establish the Bioheart Companies and in personal investment activities, as well as sponsoring the founding of World Biotech, a private investment fund specializing in biotechnology companies. See "Certain Conflicts of Interest." Scientific articles written by Mr. Leonhardt have been published in a number of publications including Techniques in Vascular and Endovascular Surgery and the Journal of Cardiovascular Surgery. Mr. Leonhardt holds a diploma in International Trade from Anoka-Hennipen Technical College and an honorary Doctorate of Engineering degree from the University of Northern California. Mr. Leonhardt currently teaches business management courses at Florida International University in Miami and the University of Northern California via video conferencing.

Michael Brown, Ph.D., M.D.
Chief Scientific Officer and Vice President of
Clinical Affairs

Dr. Michael Brown is a graduate of the University of Notre Dame with a degree in Biology with high honors and the University of Miami School of Medicine where he received his doctorate in Biochemistry and Molecular Biology. After completing this program, he entered an accelerated program and received his medical degree with his clinical interest being in the field of Internal Medicine and has applied his research knowledge to prognosis, diagnosis and prevention of diseases. His post graduate education includes fellowships in the retrovirology laboratory at the University of Miami School of Medicine and the Bascom Palmer Eye Institute where he studied the molecular basis of such diseases as HIV and Retinitus Pigmentosa. He subsequently joined the clinical thyroid laboratory at the University of Miami School of Medicine where he studied the molecular basis of Graves disease. During this time, Dr. Brown became interested in clinical research trials and has served as a consultant for various drug and device manufacturers, such as Genetech, Janssen, Parke Davis and Bristol Myers Squibb. Dr. Brown also collaborated with investigators at the Joslin Center for Diabetes at Baptist Hospital of Miami studying various diabetes therapies. In the past two years, he has been consulting with World Medical/AVE/Medtronic in F.D.A. I.D.E. Clinical trials of implantable devices for the treatment of aortic aneurysms using endovascular therapies.

Robert Lashinski
Chief Consultant Product Development

Robert Lashinski joined the Company as a consultant in September 1999, and was appointed Chief Consultant-Product Development in December 1999. Prior to joining the Company, Mr. Lashinski served as Vice President of Research and Development and as a director of AVE, a publicly-held manufacturer of coronary stents and other products for treatment of vascular disease, from January 1995 through April 1998 (after serving AVE is various capacities since July 1992), and subsequently served as a consultant to AVE from April 1998 through 1999. Mr. Lashinski was [one of the founders of AVE and was the primary designer of a number of AVE's products], including balloon catheters and coronary stents. At the time of Mr. Lashinski's retirement from AVE in 1998, AVE was the world market leader in sales of coronary stents, and AVE was subsequently acquired by Medtronic, Inc. in January 1999 in a merger transaction valued at approximately $3.7 billion. Mr. Lashinski was employed with Schneider (USA) Inc., a medical device manufacturer and subsidiary of Pfizer Inc. from October 1990 to June 1992 in both manufacturing and research and development capacities. In 1989, Mr. Lashinski was a founder of Danforth Biomedical Inc., a company focused on the research and development of vascular therapeutic devices. Prior to 1989 Mr. Lashinski served with Advanced Cardiovascular Systems, Inc., a subsidiary of Eli Lilly and Company, in the capacities of Advanced Development Engineer and Manager of Equipment Design and Development for its pilot and manufacturing facilities. Mr. Lashinski holds a B.S. degree in Mechanical Engineering from the University of Minnesota.

John L. Babitt, Jr.
CPA, Chief Financial Officer and Vice President Finance

John L. Babitt, Jr., CPA, joined the Company in December 1999, as Chief Financial Officer, Vice President-Finance and as a Director. Mr. Babitt joined the Company from Ernst & Young, LLP, where he contributed over five years in roles of increasing responsibility. Most recently, Mr. Babitt's position was Senior Manager in the Mergers & Acquisitions ("M&A") Group, where his primary responsibility involved the supervision of the acquisition/financing of businesses by financial and strategic buyers. Mr. Babitt consulted on accounting matters relevant to structuring transactions; aided in contract negotiations; performed due diligence on prospective acquisition targets; and assisted in accounting matters with respect to target SEC filings. Before joining the Ernst & Young M&A Group, Mr. Babitt was a manager with Ernst & Young's Assurance and Advisory Business Services ("AABS") Group, providing financial and accounting services primarily to technology and healthcare clients. Mr. Babitt has been involved in all aspects of SEC regulating and the initial public offering process, including preparation of annual and quarterly reports, acquisition filings, aiding with management's discussion and analysis of financial performance, assistance with SEC comments and advising on accounting issues. Prior to joining Ernst & Young, LLP, Mr. Babitt gained other relevant healthcare and accounting experience as a consultant with Bobbitt, Pittenger & Company, a regional healthcare consulting firm, and as an auditor with PriceWaterhouse, LLP. Mr. Babitt holds a Bachelor of Arts degree specializing in accounting and a Masters of Business Administration with a concentration in finance from the University of Miami. In addition, Mr. Babitt is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants.

Doris A. Taylor, Ph.D.
Chief Consultant-Heart Muscle Regeneration

Doris A. Taylor, Ph.D., was appointed Chief Consultant-Heart Muscle Regeneration and a Director of the Company in December 1999, and was also appointed to the Company's Scientific Advisory Board. Dr. Taylor is an Assistant Research Professor in the Departments of Medicine and Surgery at Duke University Medical Center, where she has conducted numerous research projects and published articles about the results of her laboratory's experiments with various heart regeneration techniques, including cellular cardiomyoplasty (a method in which autologous skeletal muscle reserve cells (myoblasts) are taken from a peripheral muscle biopsy and transplanted into damaged heart), as well as various methods of cardiac gene therapy. Dr. Taylor is the author of the first research paper confirming in vivo improvement of heart function from implants of muscle cells into the heart in animal tests.

Scott R. Bromley
Vice President of Marketing

Phone:
Web: bioheartinc.com
E-mail:

Scott R. Bromley founded Bromley Marketing in 1985 which is located in Minneapolis, Minnesota.

In 1989, Mr. Bromley became a stockholder in the World Medical Manufacturing Corporation. He was involved in the marketing strategies and printing for the corporation and worked directly from the World Medical office based out of Minneapolis. World Medical merged with Arterial Vascular Engineering, Inc. (AVE) for $62 million in AVE shares in 1998. AVE was acquired by Medtronic, Inc., the world's leading medical technology company, in early 1999 for $4.3 billion.

Currently, Mr. Bromley is operating from the Bioheart, Inc. office in Minneapolis and is a stockholder in the company. He is involved in marketing the products of the company using the latest tools in digital printing and graphic design. Mr. Bromley manages the staff at the Minneapolis location of Bioheart, Inc. and owns the 55,000 square foot building, with a clean room that Bioheart, Inc. occupies. Mr. Bromley is involved with all four of the locations within the United States.

Mr. Bromley has published the book "How to Succeed in Marketing Your Business".

Pat Chuinard
Vice President of Sales - Bioheart, Inc.

• BS, Economics - U.S. Military Academy at West Point, 1985

• MBA Management - University of Central Texas, 1989

Served 5 years in U.S. Army following graduation from West Point in 1985; Completed service as a Captain.

• 1990 to 1992: Sales Representative and Sales Trainer for Walter Lorenz Surgical, a division of Biomet, Inc. Sales Representative of the year - 1992. Territory sales increased from $ 40,000 to $1,200,000 during my tenure. Trained all new sales representatives for Walter Lorenz, Inc.

• 1992 - 1998: Cordis, a Johnson & Johnson Company. Various positions in sales, sales training, and sales management. Awards Club member; Division Manager for the Northeast U.S. (1996 to 1998).

• 1998 - 2000: Director of Sales and VP of Sales for Eclipse Surgical Technologies, Inc. Re-structured sales force in terms of representative profile, function, compensation, territory geography, training, and focused strategic objectives. Penetrated 52 of the top 100 U.S. accounts as measured by coronary bypass procedural volume by the end of 1999. The leadership, guidance, and focus that I provided led to $ 25,300,000 in sales in 1999; more than double 1998 sales level.

Next Page...

TOP OF PAGE | RETURN TO MANAGEMENT PAGE

BIOHEART, INC. | REGENESIS TECHNOLOGIES | U.S. DIALYSIS | MICROVASCULAR | SVI | DVT |